Literature DB >> 21159751

Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition.

Timothy B Johnstone1, Zhenglin Gu, Ryan F Yoshimura, Anne-Sophie Villegier, Derk J Hogenkamp, Edward R Whittemore, Jin-Cheng Huang, Minhtam B Tran, James D Belluzzi, Jerrel L Yakel, Kelvin W Gee.   

Abstract

α5 Subunit-containing GABA(A) receptors (GABA(A)Rs) and α7 neuronal nicotinic-acetylcholine receptors (nAChRs) are members of the Cys-loop family of ligand-gated ion channels (LGICs) that mediate cognitive and attentional processes in the hippocampus. α5 GABA(A)Rs alter network activity by tonic inhibition of CA1/CA3 pyramidal cells of the hippocampus. Postsynaptic α7 nAChRs in the hippocampus regulate inhibitory GABAergic interneuron activity required for synchronization of pyramidal neurons in the CA1, whereas presynaptic α7 nAChRs regulate glutamate release. Can simultaneous allosteric modulation of these LGICs produce synergistic effects on cognition? We show that combined transient application of two allosteric modulators that individually 1) inhibit α5 GABA(A)Rs and 2) enhance α7 nAChRs causes long-term potentiation (LTP) of mossy fiber stimulation-induced excitatory postsynaptic currents (EPSC) from CA1 pyramidal neurons of rat hippocampal slices. The LTP effect evoked by two compounds is replicated by 3-(2,5-difluorophenyl)-6-(N-ethylindol-5-yl)-1,2,4-triazolo[4,3-b]pyridazine (522-054), a compound we designed to simultaneously inhibit α5 GABA(A)Rs and enhance α7 nAChRs. Selective antagonists for either receptor block sustained EPSC potentiation produced by 522-054. In vivo, 522-054 enhances performance in the radial arm maze and facilitates attentional states in the five-choice serial reaction time trial with similar receptor antagonist sensitivity. These observations may translate into therapeutic utility of dual action compounds in diseases of hippocampal-based cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159751      PMCID: PMC3061525          DOI: 10.1124/jpet.110.176255

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  49 in total

1.  Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Authors:  Ann Olincy; Josette G Harris; Lynn L Johnson; Vicki Pender; Susan Kongs; Diana Allensworth; Jamey Ellis; Gary O Zerbe; Sherry Leonard; Karen E Stevens; James O Stevens; Laura Martin; Lawrence E Adler; Ferenc Soti; William R Kem; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2006-06

2.  Synaptic and nonsynaptic localization of GABAA receptors containing the alpha5 subunit in the rat brain.

Authors:  David R Serwanski; Celia P Miralles; Sean B Christie; Ashok K Mehta; Xuejing Li; Angel L De Blas
Journal:  J Comp Neurol       Date:  2006-11-20       Impact factor: 3.215

3.  Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?

Authors:  Joseph Glykys; Edward O Mann; Istvan Mody
Journal:  J Neurosci       Date:  2008-02-06       Impact factor: 6.167

4.  Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators.

Authors:  Herman J Ng; Edward R Whittemore; Minhtam B Tran; Derk J Hogenkamp; Ron S Broide; Timothy B Johnstone; Lijun Zheng; Karen E Stevens; Kelvin W Gee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 5.  The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Authors:  E Loveman; C Green; J Kirby; A Takeda; J Picot; E Payne; A Clegg
Journal:  Health Technol Assess       Date:  2006-01       Impact factor: 4.014

6.  Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats.

Authors:  Antonio Ortega-Alvaro; Juan Gibert-Rahola; Juan A Micó
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-10-13       Impact factor: 5.067

7.  Alpha5GABAA receptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons.

Authors:  Robert P Bonin; Loren J Martin; John F MacDonald; Beverley A Orser
Journal:  J Neurophysiol       Date:  2007-08-22       Impact factor: 2.714

8.  Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

9.  The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus.

Authors:  Laura Lagostena; Caryn Trocme-Thibierge; Philippe Morain; Enrico Cherubini
Journal:  Neuropharmacology       Date:  2007-12-05       Impact factor: 5.250

10.  Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist.

Authors:  David J Nutt; Marie Besson; Susan J Wilson; Gerard R Dawson; Anne R Lingford-Hughes
Journal:  Neuropharmacology       Date:  2007-08-16       Impact factor: 5.250

View more
  11 in total

Review 1.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

2.  Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity.

Authors:  Zhenglin Gu; Jerrel L Yakel
Journal:  Neuron       Date:  2011-07-14       Impact factor: 17.173

Review 3.  GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.

Authors:  Meng-Yi Xu; Albert H C Wong
Journal:  Acta Pharmacol Sin       Date:  2018-03-22       Impact factor: 6.150

4.  Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of α7 nicotinic acetylcholine receptors.

Authors:  Derk J Hogenkamp; Thomas A Ford-Hutchinson; Wen-Yen Li; Edward R Whittemore; Ryan F Yoshimura; Minhtam B Tran; Timothy B C Johnstone; Gavin D Bascom; Hannah Rollins; Lena Lu; Kelvin W Gee
Journal:  J Med Chem       Date:  2013-10-30       Impact factor: 7.446

5.  α7-nAChR agonist enhances neural plasticity in the hippocampus via a GABAergic circuit.

Authors:  Matthew Townsend; Andrew Whyment; Jean-Sebastien Walczak; Ross Jeggo; Marco van den Top; Dorothy G Flood; Liza Leventhal; Holger Patzke; Gerhard Koenig
Journal:  J Neurophysiol       Date:  2016-09-21       Impact factor: 2.714

Review 6.  Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.

Authors:  Anshul A Pandya; Jerrel L Yakel
Journal:  Biochem Pharmacol       Date:  2013-05-31       Impact factor: 5.858

Review 7.  Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease.

Authors:  Jerrel L Yakel
Journal:  Pflugers Arch       Date:  2013-01-11       Impact factor: 3.657

8.  Sniffer patch laser uncaging response (SPLURgE): an assay of regional differences in allosteric receptor modulation and neurotransmitter clearance.

Authors:  Catherine A Christian; John R Huguenard
Journal:  J Neurophysiol       Date:  2013-07-10       Impact factor: 2.714

Review 9.  Channelopathy pathogenesis in autism spectrum disorders.

Authors:  Galina Schmunk; J Jay Gargus
Journal:  Front Genet       Date:  2013-11-05       Impact factor: 4.599

10.  Adolescent Maturation of Dopamine D1 and D2 Receptor Function and Interactions in Rodents.

Authors:  Jennifer B Dwyer; Frances M Leslie
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.